847 related articles for article (PubMed ID: 19808265)
1. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial.
Yancy CW; Krum H; Massie BM; Silver MA; Stevenson LW; Cheng M; Kim SS; Evans R;
Circ Heart Fail; 2008 May; 1(1):9-16. PubMed ID: 19808265
[TBL] [Abstract][Full Text] [Related]
2. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design.
Yancy CW; Krum H; Massie BM; Silver MA; Stevenson LW; Cheng M; Kim SS; Evans R;
Am Heart J; 2007 Apr; 153(4):478-84. PubMed ID: 17383282
[TBL] [Abstract][Full Text] [Related]
3. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial).
Yancy CW; Singh A
Am J Cardiol; 2006 Jul; 98(2):226-9. PubMed ID: 16828598
[TBL] [Abstract][Full Text] [Related]
4. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial).
Yancy CW; Saltzberg MT; Berkowitz RL; Bertolet B; Vijayaraghavan K; Burnham K; Oren RM; Walker K; Horton DP; Silver MA
Am J Cardiol; 2004 Sep; 94(5):595-601. PubMed ID: 15342289
[TBL] [Abstract][Full Text] [Related]
5. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment.
Miller AH; Nazeer S; Pepe P; Estes B; Gorman A; Yancy CW
Ann Emerg Med; 2008 May; 51(5):571-8. PubMed ID: 18304693
[TBL] [Abstract][Full Text] [Related]
6. Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes.
O'Connor CM; Fiuzat M; Lindenfeld J; Miller A; Lombardi C; Carson P; Shaw LK; Wang LJ; Connolly P; Mills R; Yancy C; Mahaffey K
Am J Cardiol; 2011 Nov; 108(10):1449-57. PubMed ID: 21890092
[TBL] [Abstract][Full Text] [Related]
7. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
[TBL] [Abstract][Full Text] [Related]
8. Intermittent outpatient nesiritide infusion reduces hospital admissions in patients with advanced heart failure.
Schwarz ER; Najam S; Akel R; Sulimanjee N; Bionat S; Rosanio S
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):232-6. PubMed ID: 17875951
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC.
Mehra MR; McCluskey T; Barr M; Bourge RC; Jessup ML; Mancini D; Radovancevic B; Rayburn B; Taylor DO; Lilly-Hersley J; Linde P
Am Heart J; 2007 Jun; 153(6):932-40. PubMed ID: 17540193
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery.
Ejaz AA; Martin TD; Johnson RJ; Winterstein AG; Klodell CT; Hess PJ; Ali AK; Whidden EM; Staples NL; Alexander JA; House-Fancher MA; Beaver TM
J Thorac Cardiovasc Surg; 2009 Oct; 138(4):959-64. PubMed ID: 19660420
[TBL] [Abstract][Full Text] [Related]
11. Observation unit treatment of heart failure with nesiritide: results from the proaction trial.
Peacock WF; Holland R; Gyarmathy R; Dunbar L; Klapholz M; Horton DP; de Lissovoy G; Emerman CL
J Emerg Med; 2005 Oct; 29(3):243-52. PubMed ID: 16183441
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of serial home infusions of nesiritide for advanced heart failure.
Chung ES; Menon SG; Daly KA; Atkinson J; Peterson T; Robertson R; Ibanez K; Kereiakes DJ
Am J Cardiol; 2006 May; 97(9):1370-3. PubMed ID: 16635613
[TBL] [Abstract][Full Text] [Related]
13. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.
Colucci WS; Elkayam U; Horton DP; Abraham WT; Bourge RC; Johnson AD; Wagoner LE; Givertz MM; Liang CS; Neibaur M; Haught WH; LeJemtel TH
N Engl J Med; 2000 Jul; 343(4):246-53. PubMed ID: 10911006
[TBL] [Abstract][Full Text] [Related]
14. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Kurien S; Warfield KT; Wood CM; Miller WL
Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
[TBL] [Abstract][Full Text] [Related]
15. Treatment with B-type natriuretic peptide for chronic decompensated heart failure: insights learned from the follow-up serial infusion of nesiritide (FUSION) trial.
Yancy CW
Heart Fail Rev; 2004 Jul; 9(3):209-16. PubMed ID: 15809819
[TBL] [Abstract][Full Text] [Related]
16. Effect of nesiritide in patients with acute decompensated heart failure.
O'Connor CM; Starling RC; Hernandez AF; Armstrong PW; Dickstein K; Hasselblad V; Heizer GM; Komajda M; Massie BM; McMurray JJ; Nieminen MS; Reist CJ; Rouleau JL; Swedberg K; Adams KF; Anker SD; Atar D; Battler A; Botero R; Bohidar NR; Butler J; Clausell N; Corbalán R; Costanzo MR; Dahlstrom U; Deckelbaum LI; Diaz R; Dunlap ME; Ezekowitz JA; Feldman D; Felker GM; Fonarow GC; Gennevois D; Gottlieb SS; Hill JA; Hollander JE; Howlett JG; Hudson MP; Kociol RD; Krum H; Laucevicius A; Levy WC; Méndez GF; Metra M; Mittal S; Oh BH; Pereira NL; Ponikowski P; Tang WH; Tanomsup S; Teerlink JR; Triposkiadis F; Troughton RW; Voors AA; Whellan DJ; Zannad F; Califf RM
N Engl J Med; 2011 Jul; 365(1):32-43. PubMed ID: 21732835
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
Hernandez AF; O'Connor CM; Starling RC; Reist CJ; Armstrong PW; Dickstein K; Lorenz TJ; Gibler WB; Hasselblad V; Komajda M; Massie B; McMurray JJ; Nieminen M; Rouleau JL; Swedberg K; Califf RM
Am Heart J; 2009 Feb; 157(2):271-7. PubMed ID: 19185633
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
19. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
[TBL] [Abstract][Full Text] [Related]
20. Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients.
Chow SL; Peng JT; Okamoto MP; Heywood JT
Ann Pharmacother; 2007 Apr; 41(4):556-61. PubMed ID: 17389662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
